The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Imatinib 400 mg film-coated tablets

Fresenius Kabi Deutschland GmbHPA2059/002/002

Main Information

Trade NameImatinib 400 mg film-coated tablets
Active SubstancesImatinib mesilate
Dosage FormFilm-coated tablet
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/002/002

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE01 imatinib


License statusWithdrawn
Withdrawn Date04/12/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back